A new electronic health record-based model accurately predicted risk for gastric cancer using demographic, behavioral and ...

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of ...

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Historically, gastric cancer has been a disease primarily affecting the elderly. However, emerging research indicates a dramatic change: younger adults are now increasingly at risk, with cases ...

Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, ...